Relief Therapeutics Holding AG (RLFTF)

[GreenKnight]

100%. They were working on it as an indication for sarcoidosis prior to the COVID-19 trial when they realized their synthetic VIP (Aviptadil) bound to the molecule that Covid attacks in the lungs. That sarcoidosis trial was Phase IIb/III before all the Covid stuff came into the mix.

SO this company is so so much more than a “Covid play” and its treatment is likely very far-reaching in pulmonary distress. I am “low risk” category still for COPD but have a “condition” that could make it more likely...I am interested in a future inhaler version of sorts that might help me out if that’s a future bridge I’ve gotta cross....

$RLFTF